Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare diseases. Co.'s primary candidate is Diazoxide Choline Extended Release tablets (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. The SLNO stock yearly return is shown above.
The yearly return on the SLNO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SLNO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|